Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

736.26 -19.65 (-2.60%)
Streaming Delayed Price Updated: 10:19 AM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
76 77 Next >
Nearly Half Of S&P 500 Stocks Trade Below 50-Day Moving Average: Which One Is The Cheapest?
Nearly half of S&P 500 stocks are below 50-day moving average, indicating poor market breadth. Only top 5 companies shielded from bearish pressures. 
Via Benzinga
Topics Stocks
Exposures US Equities
What's Going On With Eli Lilly Stock Wednesday?
Eli Lilly's shares surge 25% YTD to $700 billion enterprise value. Mounjaro and Zepbound drive growth with tirzepatide. BMO Capital projects $12.78 billion FY2024 tirzepatide revenues. 
Via Benzinga
3 Perfect Stocks to Buy This Valentine's Day
These stocks have sweet long-term prospects. 
Via The Motley Fool
Amgen Takes Aim at Novo Nordisk and Eli Lilly, but Is the Stock a Buy?
It faces both clinical and competitive barriers, but they might not matter. 
Via The Motley Fool
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $6,000 Today
Via Benzinga
This Unstoppable Growth Stock Just Announced More Good News: Is It a Buy?
The drugmaker continues to impress investors. 
Via The Motley Fool
Why Shares of Eli Lilly Popped This Week
The pharmaceutical giant is gaining momentum, and investors are excited. 
Via The Motley Fool
Kerrisdale Capital Slams Altimmune (ALT) Stock in New Short Report
Kerrisdale Capital has released a short report, making clear why it is betting against ALT stock. Here's why Altimmune is likely in trouble. 
Via InvestorPlace
Altimmune Stock Sinks As Kerrisdale Capital Announces Short Position: 'Obvious Dead End'
Altimmune shares are trading lower Tuesday after short-selling investment firm Kerrisdale Capital published a new research report on the stock and announced a short position 
Via Benzinga
Move Aside, Eli Lilly and Novo Nordisk. Wall Street Thinks This Stock Will Be a Bigger Winner Over the Next 12 Months.
There's more for investors to get excited about in the biopharma world than just weight-loss drugs. 
Via The Motley Fool
Jim Cramer Warns Weight Loss Drugs Ozempic, Wegovy And Others Could Impact Food Stocks: 'That Day Will Come'
Jim Cramer, the host of CNBC's "Mad Money," has issued a warning to investors about the potential impact of weight loss drugs on the food and beverage industry. 
Via Benzinga
A Look At Pharma ETFs After Q4 Earnings
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. 
Via Talk Markets
Topics ETFs
Is Eli Lilly Stock a Buy Now?
Eli Lilly's valuation is approaching $700 billion. 
Via The Motley Fool
Eli Lilly's Weight Loss Drug Tripeptide Is Expanding Market Share, Analyst Outlines What Lies Ahead
Track Eli Lilly's tripeptide success. Weekly updates on Mounjaro and Zepbound prescriptions in the GLP-1 category. Analyst predicts $12.78 billion in fiscal year 2024 tripeptide revenues. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
2 Value Stocks With Monster Yields
These two low-priced large-cap stocks sport ginormous yields. 
Via The Motley Fool
Novo Nordisk, Eli Lilly Stride To Boost Supply Shortage For Newly Found Holy Grail Of Miraculous Weight Loss Drugs
Challenges and updates in the weight loss drug market, as Novo Nordisk and Eli Lilly address supply shortages for Wegovy and Mounjaro. Strategies to meet the increasing demand and potential market... 
Via Benzinga
Could Eli Lilly's Zepbound Become the World's Best-Selling Drug?
Everyone is excited about Zepbound, from patients to investors... 
Via The Motley Fool
Novo Nordisk Is Scaling a Barrier to Growth. Should You Buy Its Stock Now?
Even more revenue is on the way from additional sales of Wegovy. 
Via The Motley Fool
Could This Warren Buffett Advice Help You Become a Millionaire?
Both experienced and new investors may benefit from this investment... 
Via The Motley Fool
Eli Lilly Just Succeeded Where Others Failed, but Does It Matter for the Stock?
Potentially adding billions of dollars in revenue might move the needle for the pharmaceutical giant, but that could take years. 
Via The Motley Fool
3 Stocks That Could Trounce the Market in 2024
These stocks appear to have what it takes to beat the market this year. 
Via The Motley Fool
S&P 500 Hits 5,000, Magnificent 7 Tops $13 Trillion, Commercial Real Estate Cracks Emerge: The Week In The Markets
The S&P 500 index surged past 5,000, led by tech giants. Tesla falls to ninth in market cap, Novo Nordisk disrupts food industry, Ackman targets retail investors. 
Via Benzinga
Topics Stocks
Exposures US Equities
3 Stocks to Sell Immediately Before the Bubble Bursts: February 2024
These three high-flying stocks to sell are set for a major decline when the stock market bubble pops. It's time to dump them. 
Via InvestorPlace
Is Tesla Still A Magnificent 7 Stock? EV Maker Could Get Bumped By These Companies
Tesla, relegated from seventh to ninth on the mega-cap leaderboard, can give way to other companies that are more 'magnificent.' 
Via Benzinga
SPDR ETF Report For Thursday, February 8
In this video, Ira Epstein reviews the day's trading in various SPDR-ETF markets for the trading day just ended, Thursday, February 8 
Via Talk Markets
Topics ETFs
Jim Cramer Says Investors Should Look Beyond Apple, Meta And Other Magnificent 7 Stocks: 'You Might Be Missing Out On Some Huge Gains'
Jim Cramer, the host of CNBC's "Mad Money," has suggested that investors should look beyond the Magnificent Seven tech stocks for potential high-yield investments. 
Via Benzinga
Stock Market Hits Highs As AI Plays Arm, Palantir Skyrocket: Weekly Review
The S&P 500 hit 5,000. Arm, Palantir and Cloudflare rose sharply. 
Via Investor's Business Daily
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month
Investors are still excited about obesity treatments and weight-management drugs. 
Via The Motley Fool
S&P 500 Hits 5,000 Milestone, Yet Concerns Of Overvaluation Versus Its Equal-Weight Counterpart Mount
S&P 500 index at 5,000 points; caution signals emerge in comparison to equal-weight index. Magnificent Seven heavyweights contribute 64% of returns. 
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
76 77 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.